Earnings ·
Xilio Therapeutics reported financial results for the quarter ended June 30, 2026, showing a net loss of $6.4 million…
XLOXilio Therapeutics, Inc.
Xilio Therapeutics reported financial results for the quarter ended June 30, 2026, showing a net loss of $6.4 million compared to $15.8 million in the prior year period. Cash and cash equivalents stood at $136.0 million as of June 30, 2026, with management projecting a cash runway into the first quarter of 2028. The company announced FDA clearance for its IND application for XTX501, a bispecific PD-1/masked IL-2 therapy, and expects to initiate Phase 1 dosing in the second half of 2026. Additionally, Xilio is advancing IND-enabling studies for masked T cell engager programs targeting CLDN18.2 and PSMA+STEAP1, with IND submissions anticipated in the second half of 2027. Collaboration revenue increased to $18.7 million from $8.1 million year-over-year, driven by agreements with AbbVie and Gilead. Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for cancer treatment.